COMMUNIQUÉS West-GlobeNewswire

Neumora Therapeutics to Participate in Upcoming Conferences in September
02/09/2025
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel [...]
AlloFlo™ Uveo Achieves Key Milestones Ahead of Launch: 7 Peer-Reviewed Studies & 3,000 U.S. Cases
02/09/2025
Two new milestone publications confirm robust efficacy and safety profile of bio-Interventional uveoscleral outflow enhancement technology WHITE PLAINS, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Iantrek, Inc. today [...]
Kamada to Participate in Upcoming September Investor Conferences
02/09/2025
REHOVOT, Israel, and HOBOKEN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious [...]
Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
02/09/2025
BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics [...]
Seer Appoints Isaac Ro to its Board of Directors
02/09/2025
REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board [...]
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million
02/09/2025
Total consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase from initial guidance Successfully repaid term loan to Morgan Stanley Tactical Value, further [...]
Trading by management and close relations of management
02/09/2025
Please read the announcement in PDF Attachment 2025_43_Trading_By_Management
Dianabol (Dbol) Pills 2025: DBal Max Launch Dianabol Anabolic Legal Steroid Alternatives for Beginners Dosage Usage, Benefits & Results
02/09/2025
Dianabol (D-bol) Pills for Muscle Growth: Read Benefits, Dianabol Side Effects, Results, and advanced Alternatives Pills From D-Bal Max new york, Sept. 02, 2025 (GLOBE NEWSWIRE) -- August 31, 2025 | New York, (Dbal Max [...]
Military Veterans Join Virtue Recovery to Expand Community Outreach with Hope and Support
02/09/2025
LAS VEGAS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Virtue Recovery is proud to announce the expansion of its Business Development Team with the addition of two U.S. military veterans: Adam Khosroabadi, U.S. Marine Corps [...]
Hemex expands Global Clinical Network Alliance to strengthen end-to-end CRO Capabilities
02/09/2025
A newly established global alliance integrating specialized expertise in oncology, medical imaging, patient recruitment as well as pharmacokinetics and pharmacodynamics studies Comprehensive access to international [...]
OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease
02/09/2025
Collaboration leverages OMass’ Odyssion TM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease OMass to receive $20 million upfront payment, with [...]
Novaremed Announces Completion of All Patient Visits in NIH-Funded Phase 2b Trial of Non-Opioid Nispomeben for Treating Chronic Pain Associated with Diabetic Peripheral Neuropathy
02/09/2025
Last patient last visit (LPLV) was reached for the 127 adult and elderly patients enrolled into the 12-week placebo-controlled trial with nispomeben (NRD.E1) Topline results are expected in November 2025 The trial [...]
Coloplast A/S - Coloplast presents new 5-year strategy, Impact4
02/09/2025
The new 5-year strategy, Impact4 , will be presented today at the company’s Capital Markets Day 2025 The Impact4 strategy puts customers at the centre of everything we do and sets an ambitious goal for the company – to [...]
FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS
02/09/2025
Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis Oss, Netherlands – 2 September 2025 – Citryll, a biotech company [...]
CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML
02/09/2025
New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla Ventures CHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential to deliver superior [...]
Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new financial ambition towards 2030
02/09/2025
In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in line with or above [...]
ONWARD Medical Demonstrates Commercial Traction and Advances Pipeline in the First Half of 2025
02/09/2025
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, The Netherlands, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. ( [...]
Pharming Group appoints Kenneth Lynard as Chief Financial Officer
02/09/2025
Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective [...]
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
01/09/2025
– Conference Call and Webcast to be held Tuesday, September 2, 2025, at 8:00 a.m. ET – WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments [...]

Pages